The CARDIO-TTRansform study is currently enrolling participants to evaluate the safety and efficacy of eplontersen, an investigational antisense RNA-targeted therapy, for people living with hereditary and wild-type cardiac amyloidosis.

In a phase I, randomized, placebo-controlled study, eplontersen given at a 45 mg, 60 mg or 90 mg dose, by subcutaneous injection every four weeks in 36 healthy volunteers achieved a mean reduction in serum TTR of 86%, 91% and 94%, respectively, compared to baseline.

Interested in learning more about the CARDIO-TTRansform study?

Information regarding the Ionis CARDIO-TTRansform trial can be downloaded below or Click Here

About ATTR Amyloidosis
 About the CARDIO-TTRansform Clinical Trial 
Cardio-TTRansform Trial Frequently Asked Questions
Cardio-TTRansform Information

Notable publications about ATTR-CM and eplontersen:

If you know of or have patients that may benefit from joining the CARDIO-TTRansform study, please contact us at [email protected] or 844-413-0219. We look forward to hearing from you and working with you throughout this trial.